Recent Updates
Recently added Catalysts
TVTX Positive Sentiment

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thursday, November 12, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Travere Therapeutics announced inducement equity grants to 20 new employees on November 10, 2026. These grants include restricted stock units totaling 65,520 shares. The grants were made outside of the company's 2018 Equity Incentive Plan, indicating a strategic move to attract talent.

Market Sentiment Analysis

POSITIVE FACTORS

  • Inducement grants to 20 new employees.
  • Total of 65,520 shares granted.
  • Supports company growth and talent acquisition.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
10.2%
average across 11 past catalysts
Lead asset
L-Citrulline
Phase 3 · Sickle Cell Disease

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on November 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 20 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 65,520 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted a

Frequently Asked Questions

What are the inducement grants announced by Travere?

Travere announced inducement equity grants to 20 new employees.

How many shares were granted in the inducement grants?

A total of 65,520 shares were granted.

When were the inducement grants made?

The inducement grants were made on November 10, 2026.

What plan are the inducement RSUs associated with?

They are associated with Travere's 2018 Equity Incentive Plan.

ShareAdd on Google
Tags: TVTX Travere Therapeutics equity grants restricted stock units 2018 Equity Incentive Plan
Last updated: Nov 12, 2026

Biotech snapshot

Cash runway
$472M liquidity · $0M/mo burn
Low dilution risk
Lead asset
L-CitrullinePhase 3
Sickle Cell Disease →

Catalyst track record

+24%
best trade around TVTX's most recent catalyst

Peak hindsight return over a 120-day window, across 11 tracked FDA/PDUFA catalysts for TVTX.

See every catalyst's timing & PoA →